Peter Forsyth, MD

home / authors / peter-forsyth-md

Articles

Peter Forsyth, MD

Dr Forsyth on a Phase 1 Study Evaluating Intrathecal cDC1s in Leptomeningeal Disease

Peter Forsyth, MD
November 20th 2024

Peter Forsyth, MD, discusses the design of a first-in-human phase 1 trial evaluating HER2/HER3–targeted intrathecal dendritic cells in leptomeningeal disease.

Read More

Peter Forsyth, MD

Dr Forsyth on the Potential Utility of Intrathecal cDC1s in Leptomeningeal Disease

Peter Forsyth, MD
August 27th 2024

Peter Forsyth, MD, discusses the evaluation of intrathecal dendritic cells for patients with TNBC/HER2-positive leptomeningeal disease.

Read More

Peter Forsyth, MD

Dr Forsyth on Leptomeningeal Disease in HER2+ Breast Cancer and TNBC

Peter Forsyth, MD
June 18th 2024

Peter Forsyth, MD, discusses the importance of evaluating leptomeningeal disease caused by TNBC and HER2+ breast cancer.

Read More

Julia Foldi, MD, PhD

Dr Forsyth on the Investigation of Intrathecal Dendritic Cells for HER2+/TNBC Leptomeningeal Disease

Peter Forsyth, MD
June 11th 2024

Peter Forsyth, MD, discusses a study of intrathecal dendritic cells in patients with leptomeningeal disease from TNBC or HER2-positive breast cancer.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need